{"id":43233,"date":"2025-10-14T14:23:54","date_gmt":"2025-10-14T06:23:54","guid":{"rendered":"https:\/\/flcube.com\/?p=43233"},"modified":"2025-10-14T14:23:55","modified_gmt":"2025-10-14T06:23:55","slug":"everest-medicines-commences-global-phase-i-trial-of-universal-mrna-cancer-vaccine-evm14","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43233","title":{"rendered":"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14"},"content":{"rendered":"\n<p><strong>Everest Medicines Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) announced today that the first patient has been successfully dosed in its global, multi\u2011center Phase\u202fI clinical trial of the universal, off\u2011the\u2011shelf therapeutic mRNA cancer vaccine <strong>EVM14 Injection<\/strong>. The dose was administered at <strong>NEXT Oncology Virginia<\/strong>, a leading clinical research site in the United States.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class Platform<\/strong> \u2013 EVM14 is built on Everest\u2019s proprietary mRNA technology, targeting <strong>five tumor\u2011associated antigens (TAAs)<\/strong> in a single, off\u2011the\u2011shelf formulation.<\/li>\n\n\n\n<li><strong>Broad Indication Spectrum<\/strong> \u2013 Designed for <strong>squamous non\u2011small cell lung cancer (sq\u2011NSCLC)<\/strong> and <strong>head &amp; neck squamous cell carcinoma (HNSCC)<\/strong>, with potential expansion to other squamous cell carcinomas.<\/li>\n\n\n\n<li><strong>Mechanism of Action<\/strong> \u2013 After intramuscular injection, EVM14 is taken up by antigen\u2011presenting cells (APCs) and translated into target antigens. These antigens are displayed on MHC molecules, activating antigen\u2011specific T cells that migrate to tumor sites and kill antigen\u2011expressing cells.<\/li>\n\n\n\n<li><strong>Global Trial Milestone<\/strong> \u2013 The first patient dose marks a critical step toward demonstrating safety, tolerability, and preliminary efficacy of the vaccine.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scientific-amp-commercial-context\">Scientific &amp; Commercial Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>mRNA Vaccine Momentum<\/strong> \u2013 Building on the success of mRNA platforms in infectious disease, Everest is pioneering oncology applications, addressing unmet needs in squamous cancers.<\/li>\n\n\n\n<li><strong>Strategic Partnerships<\/strong> \u2013 The trial is conducted in collaboration with NEXT Oncology, leveraging its expertise in squamous tumor trials and access to a diverse patient population.<\/li>\n\n\n\n<li><strong>Future Outlook<\/strong> \u2013 Successful Phase\u202fI results will pave the way for Phase\u202fII studies and accelerated development timelines, aligning with Everest\u2019s goal to bring next\u2011generation mRNA therapeutics to patients worldwide.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-everest-medicines\">About Everest\u202fMedicines<\/h3>\n\n\n\n<p>Everest\u202fMedicines Limited is a Hong\u202fKong\u2011listed biopharmaceutical company focused on the discovery, development, and commercialization of next\u2011generation mRNA therapeutics for oncology and other disease areas. The company\u2019s pipeline includes a range of mRNA vaccines and therapeutics designed to elicit robust, antigen\u2011specific immune responses.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-evm14\">About EVM14<\/h3>\n\n\n\n<p>EVM14 Injection is a universal, off\u2011the\u2011shelf therapeutic mRNA cancer vaccine targeting five tumor\u2011associated antigens. It represents a novel approach to treat multiple squamous cell carcinomas through a single, scalable platform.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43235,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,126,1164,12],"class_list":["post-43233","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-everest-medicines","tag-hkg-1952","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed in its global, multi\u2011center Phase\u202fI clinical trial of the universal, off\u2011the\u2011shelf therapeutic mRNA cancer vaccine EVM14 Injection. The dose was administered at NEXT Oncology Virginia, a leading clinical research site in the United States.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43233\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed in its global, multi\u2011center Phase\u202fI clinical trial of the universal, off\u2011the\u2011shelf therapeutic mRNA cancer vaccine EVM14 Injection. The dose was administered at NEXT Oncology Virginia, a leading clinical research site in the United States.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43233\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-14T06:23:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-14T06:23:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14\",\"datePublished\":\"2025-10-14T06:23:54+00:00\",\"dateModified\":\"2025-10-14T06:23:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233\"},\"wordCount\":360,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1402.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Everest Medicines\",\"HKG: 1952\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43233#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43233\",\"name\":\"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1402.webp\",\"datePublished\":\"2025-10-14T06:23:54+00:00\",\"dateModified\":\"2025-10-14T06:23:55+00:00\",\"description\":\"Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed in its global, multi\u2011center Phase\u202fI clinical trial of the universal, off\u2011the\u2011shelf therapeutic mRNA cancer vaccine EVM14 Injection. The dose was administered at NEXT Oncology Virginia, a leading clinical research site in the United States.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43233\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1402.webp\",\"width\":1080,\"height\":608,\"caption\":\"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43233#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14 - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed in its global, multi\u2011center Phase\u202fI clinical trial of the universal, off\u2011the\u2011shelf therapeutic mRNA cancer vaccine EVM14 Injection. The dose was administered at NEXT Oncology Virginia, a leading clinical research site in the United States.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43233","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14","og_description":"Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed in its global, multi\u2011center Phase\u202fI clinical trial of the universal, off\u2011the\u2011shelf therapeutic mRNA cancer vaccine EVM14 Injection. The dose was administered at NEXT Oncology Virginia, a leading clinical research site in the United States.","og_url":"https:\/\/flcube.com\/?p=43233","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-14T06:23:54+00:00","article_modified_time":"2025-10-14T06:23:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43233#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43233"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14","datePublished":"2025-10-14T06:23:54+00:00","dateModified":"2025-10-14T06:23:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43233"},"wordCount":360,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43233#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1402.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Everest Medicines","HKG: 1952","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43233#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43233","url":"https:\/\/flcube.com\/?p=43233","name":"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43233#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43233#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1402.webp","datePublished":"2025-10-14T06:23:54+00:00","dateModified":"2025-10-14T06:23:55+00:00","description":"Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed in its global, multi\u2011center Phase\u202fI clinical trial of the universal, off\u2011the\u2011shelf therapeutic mRNA cancer vaccine EVM14 Injection. The dose was administered at NEXT Oncology Virginia, a leading clinical research site in the United States.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43233#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43233"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43233#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1402.webp","width":1080,"height":608,"caption":"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43233#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Commences Global Phase\u202fI Trial of Universal mRNA Cancer Vaccine EVM14"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1402.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43233"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43233\/revisions"}],"predecessor-version":[{"id":43238,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43233\/revisions\/43238"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43235"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}